Free Trial
NASDAQ:GANX

Gain Therapeutics (GANX) Stock Price, News & Analysis

$1.38
+0.02 (+1.47%)
(As of 07/12/2024 ET)
Today's Range
$1.34
$1.39
50-Day Range
$1.12
$2.90
52-Week Range
$1.11
$5.33
Volume
273,476 shs
Average Volume
518,018 shs
Market Capitalization
$24.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.25

Gain Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
497.8% Upside
$8.25 Price Target
Short Interest
Healthy
1.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.83mentions of Gain Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$20,740 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.03) to ($1.11) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.94 out of 5 stars

Medical Sector

373rd out of 915 stocks

Pharmaceutical Preparations Industry

174th out of 433 stocks

GANX stock logo

About Gain Therapeutics Stock (NASDAQ:GANX)

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

GANX Stock Price History

GANX Stock News Headlines

Gain Therapeutics' (GANX) Buy Rating Reaffirmed at HC Wainwright
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Gain Therapeutics Announces Proposed Public Offering
See More Headlines
Receive GANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/14/2024
Today
7/14/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GANX
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.25
High Stock Price Target
$10.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+497.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-22,270,000.00
Pretax Margin
-40,210.22%

Debt

Sales & Book Value

Annual Sales
$50,000.00
Book Value
$0.97 per share

Miscellaneous

Free Float
15,940,000
Market Cap
$24.91 million
Optionable
Optionable
Beta
0.35
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Khalid Islam Ph.D. (Age 69)
    Founder & Chairman
    Comp: $75k
  • Mr. Matthias Alder LIC. IUR. (Age 59)
    LL.M., President, CEO & Director
    Comp: $593k
  • Mr. Gene Mack M.B.A.
    Chief Financial Officer
  • Dr. Manolo Bellotto Ph.D. (Age 53)
    GM & Chief Strategy Officer
    Comp: $251.99k
  • Dr. Joanne Taylor Ph.D.
    Senior Vice President of Research
  • Dr. Terenzio Ignoni Pharm.D.
    Senior Vice President of Technical Operations
  • Dr. Jonas Hannestad M.D.
    Ph.D., Chief Medical Officer

GANX Stock Analysis - Frequently Asked Questions

How have GANX shares performed this year?

Gain Therapeutics' stock was trading at $3.27 at the beginning of 2024. Since then, GANX stock has decreased by 57.8% and is now trading at $1.38.
View the best growth stocks for 2024 here
.

How were Gain Therapeutics' earnings last quarter?

Gain Therapeutics, Inc. (NASDAQ:GANX) released its earnings results on Tuesday, May, 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.08.

When did Gain Therapeutics IPO?

Gain Therapeutics (GANX) raised $40 million in an initial public offering on Thursday, March 18th 2021. The company issued 3,600,000 shares at a price of $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. served as the underwriters for the IPO and National Securities Corp. was co-manager.

How do I buy shares of Gain Therapeutics?

Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GANX) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners